Clinical trials: Lower Urinary Tract Symptoms
Overactive Bladder
Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB)
The aim of the study is to determine how well the drug BAY1817080 works in OAB patients with urgency urinary incontinence (UUI), defined as involuntary leakage of urine, accompanied or immediately preceded by a sudden compelling…
- Trial name
- OVADER (NCT04545580)
- Testing
- BAY1817080
- Where
- 28 sites in Australia, Austria and 7 more
- Volunteers
- 99 people
- Sponsor
- Bayer
Urinary Urge Incontinence (UUI), Urinary Frequency (UF)
F15 Recharge Free Axonics SNM System Clinical Study
Multicenter, prospective, non randomized, single arm evaluation of patients with overactive bladder (OAB) and/or fecal incontinence (FI) employing the Axonics recharge free SNM System.
- Conditions
- Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)
- Trial name
- NCT06186765
- Testing
- Axonics SNM System (Model 4101)
- Where
- 16 sites in United States, Netherlands and 1 more
- Volunteers
- 144 people
- Sponsor
- Axonics, Inc.
Urinary Tract Infections
Comparison of Pre-procedural PCR and Culture-based UTI Assessment Prior to Intravesical Botox Injection
This study is a retrospective record review to determine whether a novel multiplex PCR assay can be utilized as a screening method for UTI in patients receiving Botox injection to treat overactive bladder (OAB).
- Trial name
- NCT04817865
- Testing
- Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST), Urine Culture
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pathnostics
Overactive Bladder
Overactive Bladder Innovative Therapy Trial (OrBIT)
The purpose of this study is to compare percutaneous tibial nerve stimulation (PTNS) to drug therapy for the treatment of symptoms of overactive bladder (OAB).
- Trial name
- OrBIT (NCT00448175)
- Testing
- Urgent PC Neuromodulation System, Tolterodine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Uroplasty, Inc
Urinary Bladder, Overactive, Urinary Incontinence
Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
This study will evaluate the efficacy and safety of onabotulinumtoxinA 100 U (BOTOX®), compared to placebo, when injected into the bladder using an alternative injection paradigm in reducing the number of daily urinary…
- Trial name
- LO-BOT (NCT03052764)
- Testing
- onabotulinumtoxinA
- Where
- 31 sites in United States
- Volunteers
- 120 people
- Sponsor
- Allergan
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Omega Study: Evaluation of the Safety and Efficacy of the Omega System for the Treatment of BPH
The ProArc Medical Omega system is a prostatic reshaping device that is designed to treat Lower Urinary Tract Symptoms (LUTS) due to BPH.
- Trial name
- NCT04627701
- Testing
- Omega
- Where
- 4 sites in Israel, New Zealand
- Volunteers
- 26 people
- Sponsor
- ProArc Medical
Stress Urinary Incontinence (SUI)
A Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS)
Prospective, multicenter, single-arm study
- Trial name
- SOPHIA2 (NCT06968741)
- Testing
- Artificial Urinary Sphincter (AUS)
- Where
- 21 sites in United States, France
- Volunteers
- 140 people
- Sponsor
- UroMems SAS
Overactive Bladder (OAB)
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine
- Trial name
- NCT00507169
- Testing
- SVT-40776
- Sponsor
- Salvat
Advanced Prostate Cancer, Lower Urinary Tract Symptoms
Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)
The purpose of the study is to determine the influence of GnRH (gonadotropin releasing hormone) analogue - Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine) administration on intensity of lower urinary tract symptoms…
- Trial name
- LEMON (NCT01078545)
- Testing
- Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)
- Where
- 143 sites in Poland, Ukraine
- Volunteers
- 729 people
- Sponsor
- Abbott
Healthy
A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval
The purpose of this study is to assess the electrocardiogram (ECG) effects of fedovapagon dose administration relative to placebo in healthy adult male and female subjects.
- Trial name
- NCT02537288
- Testing
- Fedovapagon, Moxifloxacin
- Where
- Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Vantia Ltd
Overactive Bladder (OAB)
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.
- Trial name
- PILLAR (NCT02216214)
- Testing
- Mirabegron
- Where
- 120 sites in United States, Canada
- Volunteers
- 888 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Urinary Tract Infection
Safety and Efficacy of PP4001 for the Treatment of Symptoms Associated With Uncomplicated Urinary Tract Infection
PP4001 is a medication not yet approved by the US FDA. This is a phase 2, multi-center, randomized, double-blind study of 3 doses of PP4001 versus placebo in the treatment of symptoms associated with uncomplicated urinary tract…
- Trial name
- NCT01406587
- Testing
- PP4001
- Where
- 25 sites in United States
- Volunteers
- 261 people
- Sponsor
- Pinnacle Pharmaceuticals, Inc.
Overactive Bladder
A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder
The purpose of this study is to determine the effect of repeat doses of solabegron and oxybutynin when taken alone or together
- Trial name
- NCT00501267
- Testing
- solabegron and oxybutynin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Female Urogenital Diseases, Urinary Incontinence
Clinical Trial of "Magic Gyno" Laser Device
The aim of this prospective study is investigation of efficiency and safety of medical device "Magic Gyno" in accordance with the stated purpose.
- Conditions
- Female Urogenital Diseases, Urinary Incontinence, Prolapse Genital, Menopausal Syndrome
- Trial name
- NCT05463081
- Testing
- Laser treatment, Blood test, Clinical urine test
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- MeLSyTech, Ltd
Cystoscope, Bladder Cancer
Single-use Cystoscope System for Direct Visualization of the Urethra and Bladder
In this study, the new aScope 4 Cysto is used to see how well it visualizes the lower urinary tract, and if this new flexible cystoscope performs as well as other routinely used cystoscopes.
- Conditions
- Cystoscope, Bladder Cancer, Lower Urinary Tract Symptoms
- Trial name
- NCT04190641
- Testing
- Ambu aScope 4 Cysto and aView Urologia
- Where
- Denmark
- Volunteers
- 4 people
- Sponsor
- Ambu A/S
Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
This is a randomized, double-blind, controlled, non-inferiority multicenter Phase III clinical study to evaluate the efficacy and safety of H077 sustained-release tablets versus silodosin capsules in treating benign prostatic…
- Trial name
- NCT07146386
- Testing
- H077 sustained-release tablet, Silodosin capsules Control Group
- Where
- 66 sites in China
- Volunteers
- 728 people
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
Overactive Bladder
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
1. Primary Objective: To evaluate the dose-response relationship of tarafenacin on efficacy. 2. Secondary Objectives: To compare 12 weeks' efficacy of different doses of tarafenacin to that of placebo in patients suffering from…
- Trial name
- NCT01458197
- Testing
- Tarafenacin 0.2 mg, Tarafenacin 0.4 mg
- Where
- South Korea
- Volunteers
- 235 people
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Prostatic Hyperplasia, Prostate
Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems
Study to look at safety and effectiveness of different doses of tadalafil on prostate related genital/urinary tract problems.
- Trial name
- PILUTS (NCT00547625)
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Eli Lilly and Company
Stress Urinary Incontinence
A Post-Market Study of the AMS AdVance™ Male Sling System for the Treatment of Male Stress Urinary Incontinence
A prospective, multi-center study of the AdVance Male Sling for Stress Urinary Incontinence. The purpose of this study is to obtain surgical technique data for use in physician education and training and to collect early clinical…
- Trial name
- NCT00998790
- Testing
- American Medical Systems (AMS) AdVance™ Male Sling System
- Where
- 3 sites in Belgium, France
- Volunteers
- 114 people
- Sponsor
- Boston Scientific Corporation
Urinary Incontinence, Stress
Evaluate Safety and Efficacy of Duloxetine in Predominant Stress Urinary Incontinence
The purposes of this study are to determine whether duloxetine can help subjects with stress urinary incontinence and to see whether the effects of duloxetine can be maintained.
- Trial name
- NCT00190996
- Testing
- Duloxetine Hydrochloride
- Where
- United Kingdom
- Volunteers
- 2,765 people
- Sponsor
- Eli Lilly and Company